RecruitingPhase 1NCT07280013

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Sponsor

C4 Therapeutics, Inc.

Enrollment

60 participants

Start Date

Feb 6, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma (MM)

Summary

The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a combination of two drugs — cemsidomide and elranatamab — for people with multiple myeloma (a blood cancer in the bone marrow) that has returned or stopped responding to previous treatments. **You may be eligible if...** - You have a confirmed diagnosis of multiple myeloma - You have measurable disease - You have received 2–4 prior treatment lines (escalation part) or 1–3 prior lines (expansion part), including at least one immunomodulatory drug - You are in reasonably good health (ECOG 0–2) **You may NOT be eligible if...** - You have active plasma cell leukemia, smoldering myeloma, POEMS syndrome, or light chain amyloidosis - You have had a stem cell transplant within the past 12 weeks, or have active graft-versus-host disease - You have an active, uncontrolled infection - You have been previously treated with a BCMA-targeted immunotherapy (T-cell engager or CAR-T therapy) - You have difficulty swallowing tablets or significant gut absorption problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCemsidomide

IKZF1/3 degrader

BIOLOGICALElranatamab

• BCMA-CD3 bispecific antibody

Locations(16)

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States

UCLA Health, Jonsson Comprehensive Cancer Center

Santa Monica, California, United States

Tampa General Hospital

Tampa, Florida, United States

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States

Loyola University Medical Center

Maywood, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

Norton Cancer Institute St. Matthews

Louisville, Kentucky, United States

University of Maryland Greenbaum Comprehensive Cancer Center

Baltimore, Maryland, United States

START Midwest

Grand Rapids, Michigan, United States

University of Nebraska

Omaha, Nebraska, United States

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Perlmutter Cancer Center at NYU Langone Hospital

Brooklyn, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Duke Cancer Center

Durham, North Carolina, United States

MD Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07280013

Related Trials

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

NCT0697478611 locations

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

NCT072143244 locations

Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma

NCT075470072 locations

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

NCT0710752929 locations

CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)

NCT073421791 location